期刊
ANNALS OF THE RHEUMATIC DISEASES
卷 71, 期 11, 页码 1761-1764出版社
BMJ PUBLISHING GROUP
DOI: 10.1136/annrheumdis-2012-202021
关键词
-
类别
资金
- MRC Clinician Scientist Fellowship [G0902272]
- Canadian Arthritis Network Postdoctoral Award
- MRC [G0902272] Funding Source: UKRI
- Medical Research Council [G0902272] Funding Source: researchfish
- National Institute for Health Research [CL-2008-06-003] Funding Source: researchfish
Glucocorticoids are one of the most frequently prescribed therapies in rheumatology, a reflection of their effectiveness as a powerful anti-inflammatory drug. Glucocorticoids are also, however, associated with a wide range of adverse events, particularly at higher doses. To make appropriate decisions, doctors and patients need to weigh these benefits against the potential harms. This article describes the many uncertainties which make informed prescribing difficult. We lack knowledge, for example, on the magnitude of risk, the relationship to dose and duration, and what happens to risk on stopping therapy. Beyond safety, we describe how patients may lack understanding of the nature of the benefits and harms, and how to incorporate value judgements which are crucial to the decision making process. We conclude by exploring how future research might fill these knowledge gaps to enable a better informed decision process.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据